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Abstract. 
 
We have used the selective farnesylation in-
 
hibitor HR12 [cysteine-
 
N
 
(methyl)valine-
 
N
 
(cyclohexyl)
glycine-methionine-
 
O
 
-methyl-ester] to study the role of
oncogenic Ras in cytoskeletal reorganization in Ha-
 
ras
 
V12
 
-transformed Rat1 cells (Rat1/ras). Application of
HR12 resulted in complete restoration of the cytoskele-
ton and associated cell adhesions disrupted by oncogenic
Ras. This included an increase in the number and size of
focal adhesions, accompanied by massive stress ﬁber for-
mation and enhanced tyrosine phosphorylation. Further-
more, HR12 induced assembly of adherens junctions and
dramatically elevated the level of the junctional compo-
 
nents, cadherin and 
 
b
 
-catenin. HR12 was unable to re-
store the nontransformed phenotype in cells expressing
farnesylation-independent, myristylated Ras. Examina-
tion of the main Ras-regulated signaling pathways re-
vealed that HR12 induced a dose- and time-dependent
 
decline in Erk1&2 activation (
 
t
 
1/2 
 
z 
 
6 h), which corre-
lated with the accumulation of nonfarnesylated onco-
genic-Ras. Inhibition of the Mek/Erk pathway in Rat1/
ras cells, using the Mek inhibitor, PD98059, resulted in
complete cytoskeletal recovery, indistinguishable from
that induced by HR12. Moreover, a constitutively active
Mek mimicked the effect of 
 
ras
 
 transformation in Rat1
cells, and prevented HR12-induced cytoskeletal effects
in Rat1/ras cells. No such effects were observed after
treatment of Rat1/ras cells with the phosphatidylinositol
3-kinase inhibitor LY294002. These ﬁndings establish the
Mek/Erk pathway as the dominant pathway involved in
conferring the cytoskeletal and junctional manifestations
of the Ras-induced transformed phenotype.
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Introduction
 
Activating mutations in 
 
ras
 
 genes are found in 
 
z
 
30% of all
human cancers, especially in colon and pancreatic carcino-
mas (50 and 90%, respectively) (Bos, 1989; Der, 1989). On-
cogenic Ras is important in tumor initiation as well as in tu-
mor maintenance (Chin et al., 1999). The pivotal role of
Ras in human cancer has received attention from both mo-
lecular oncologists and drug designers. As the transforming
 
activity of oncogenic Ras is dependent on its anchorage
 
to the plasma membrane (Hancock et al., 1989; Jackson
et al., 1990), prevention of Ras translocation to the mem-
brane was established as a strategy for inhibition of its
biochemical and pathological activities (Gibbs et al., 1994).
Ras attachment to the membrane is dictated through its
COOH-terminal CAAX sequence, which undergoes three
post-translational modifications (Zhang and Casey, 1996).
The first modification is farnesylation, in which a farnesyl
(C15 isoprenoid) moiety is covalently attached to the cys-
 
teine residue of the CAAX motif. After farnesylation, AAX
residues are cleaved and Ras undergoes COOH-terminal
methyl esterification. The farnesylated Ras proteins also
use other anchoring signals to enhance their attachment to
the membrane; e.g., palmitoylation of an upstream cysteine
or existence of a polybasic sequence (Hancock et al., 1990).
Since farnesylation is obligatory for Ras oncogenicity
 
(Kato et al., 1992), farnesyltransferase inhibitors (FTIs)
 
1
 
were sought as a strategy to block Ras-mediated signal
transduction and Ras-induced tumorigenesis. Indeed, FTIs
have been shown to block Ras attachment to the mem-
brane and to reverse Ras-dependent transformation and
suppress anchorage-independent cell growth. Further-
more, using xenograft or transgenic mouse models, FTIs
were shown to prevent tumor growth and elicit tumor re-
gression, in the absence of detectable toxic side effects (re-
viewed in Prendergast, 2000). We have recently reported
on a novel FTI, HR12 [cysteine-
 
N
 
(methyl)valine-
 
N
 
(cyclo-
hexyl)glycine-methionine-
 
O
 
-methyl-ester], which is selec-
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Abbreviations used in this paper:
 
 Erk, extracellular-signal regulated ki-
nase; FTI, farnesyltransferase inhibitor; Jnk, Jun NH
 
2
 
-terminal kinase;
MAPK, mitogen activated protein kinase; Mek, MAPK kinase; PI-
 
3
 
9
 
kinase, phosphatidylinositol 3-kinase; PKB, protein kinase-B/c-Akt.  
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tive and potent (Reuveni et al., 1997). Here, we show for
the first time the biochemical effects of HR12, and its bio-
logical effects on cell-adhesion and cytoskeletal reorgani-
zation in 
 
ras
 
-transformed cells.
Transformed cells often show altered patterns of cyto-
skeletal protein expression, and commonly display a disorga-
nized actin cytoskeleton. This phenotype is associated with
the poor adhesiveness of transformed cells, their enhanced
motility, and ability to grow in an anchorage-independent
fashion (Hunter, 1997; Behrens, 1999; Christofori and
Semb, 1999). In particular, transformation of cells by con-
stitutively activated Ras results in the loss of adherens
junctions and stress fibers (Izawa et al., 1998; Potempa and
Ridley, 1998). Application of FTI to 
 
ras
 
-transformed fi-
broblasts was reported to induce stress-fiber formation
and increase cell spreading (Prendergast et al., 1994). In
the present study, we show a major and pleotropic pheno-
typic reversion of Rat1/ras cells induced by HR12, includ-
ing: (a) a dramatic increase in the stress fiber organization,
(b) similar increases in focal contact formation and ty-
rosine phosphorylation, (c) increases in the levels of cad-
herin and 
 
b
 
-catenin, and (d) assembly of cadherin- and
catenin-rich adherens junctions. Both cell–matrix and cell–
cell adhesions play important roles in growth control (St.
Croix et al., 1998; Levenberg et al., 1999) and tumorigene-
sis (Perl et al., 1998; Christofori and Semb, 1999). In this
report, FTI is shown, for the first time, to induce a marked
increase in cadherin and 
 
b
 
-catenin levels and recovery of
adherens junctions, suggesting a new mechanism for FTI-
mediated phenotypic reversion and growth inhibition.
We show that the extracellular-signal regulated kinase
(Erk) pathways is inhibited by HR12 treatment. We fur-
ther show that the inhibition of mitogen-activated protein
kinase (MAPK) kinase (Mek) induces morphological re-
version of Rat1/ras cells indistinguishable from that of
HR12. The expression of constitutively active Mek in
Rat1/ras cells prevents HR12-induced cytoskeletal recov-
ery, suggesting that the Mek/Erk pathway plays a major
role in the Ras-induced oncogenic phenotype.
 
Materials and Methods
 
Materials
 
HR12 was synthesized, followed by semipreparative RPHPLC to 
 
.
 
90%
purity, as described (Reuveni et al., 1997). The molecular weight of
the pure product was determined by mass spectroscopy (518 D). Its 
 
k
 
9
 
value was 5.2, and its residue configuration was verified (CAT).
PD98059, LY294002, and SB203580 were obtained from Calbiochem.
MAPKK1(
 
D
 
N3) cDNA was a generous gift from N.G. Ahn (University of
California at San Diego, La Jolla, CA). Dominant-negative SEK (SEK-
AL) cDNA was generously obtained from B. Zanke (University of Tor-
onto, Toronto, Ontario, Canada).
 
Antibodies
 
Immunocytochemistry. 
 
Anti–
 
b
 
-catenin and anti-paxillin mAb were from
Transduction Laboratories (dilution 1:20 in PBS), anti-vinculin and anti-
phosphotyrosine (PT-66) mAb were from Sigma-Aldrich (dilution 1:20
and 1:30 in PBS). Secondary antibody Cy3-conjugated goat anti–mouse
IgG was from Jackson ImmunoResearch Laboratories (dilution 1:80).
 
Immunoblotting. 
 
Anti–pan-cadherin mAb (CH-19; dilution 1:2,000) and
anti–diphospho(Thr183/Tyr185) ERK-1&2 mAb (dilution 1:10,000) were
from Sigma-Aldrich. Polyclonal anti–ERK-2 (C-14; dilution 1:10,000),
polyclonal anti–p38 (C-20; dilution 1:2,000), polyclonal anti–Akt1/2
(H-136; dilution 1:1,000), polyclonal anti–Jnk1 (C-17; dilution 1:2,000) were
from Transduction Laboratories. Polyclonal anti–diphospho(Thr180/
 
Tyr182)-p38 MAPK (dilution 1:500), polyclonal antiphospho(Thr308)-
Akt (dilution 1:1,000), and polyclonal anti–diphospho(Thr183/Tyr185)-
SAPK/Jnk (dilution 1:500) were from New England Biolabs, Inc. Anti-
Ras antibody was produced from Hybridoma Y13-259. HRP-conjugated
secondary antibodies were obtained from Jackson ImmunoResearch Lab-
oratories (dilution 1:10,000).
 
Cell Culture and Transfection
 
Rat1 fibroblasts were obtained from M. Oren (Weizmann Institute, Reho-
vot, Israel). Ha-
 
ras
 
V12
 
–transformed Rat1 (Rat1/ras) cells were constructed
in our laboratory by J. Axelrod, who transformed Rat1 cells with EJ Ras 6.6
DNA from R. Weinberg (Whitehead Institute, Cambridge, MA). NIH3T3,
Ha-
 
ras
 
V12
 
–transformed NIH3T3 (NIH3T3v-ras) and myristoylated-
 
ras–
 
transformed NIH3T3 (NIH3T3myr-ras) were obtained from D.R. Lowy
(National Cancer Institute, Bethesda, MD). All cells were grown in DME
supplemented with 10% FCS (Bet-Haemek). All treatments described in
this report were performed in DME containing 10% FCS. Transient trans-
fection of Rat1/ras and Rat1 cells was performed by electroporation as fol-
lows. 5 
 
3 
 
10
 
6
 
 cells were suspended in 0.3 ml of serum-free medium and
mixed with 5–7 
 
m
 
g of plasmid expressing MAPKK1(
 
D
 
N3) or SEK-AL and 5
 
m
 
g plasmid expressing GFP, at room temperature, in a 0.4 cm cuvette (Bio-
Rad Laboratories). The mixture was electroporated at 220 V, 960 
 
m
 
F and,
after a 5-min incubation, the transfected cells were introduced into DME
containing 10% FCS and seeded onto coverslips.
 
Immunostaining
 
Cells were plated on coverslips in DME containing 10% FCS and main-
tained at 37
 
8
 
C with 5% CO
 
2
 
. 24 h after seeding, the medium was replaced
with fresh medium containing 20 
 
m
 
M HR12, 50 
 
m
 
M PD98059, 10 
 
m
 
M
LY294002, 10 
 
m
 
M SB203580, or 0.05% DMSO (veh). The medium with
the inhibitor was replaced every 24 h where applicable. Fixation was per-
formed at 37
 
8
 
C, as follows. Cells were washed once with PBS, fixed, and
permeabilized in a solution containing 3% paraformaldehyde, 50 mM
MES buffer, pH 6, 0.5% Triton X-100, and 5 mM CaCl
 
2
 
, for 30 s, followed
by a 1-h incubation in the same solution without Triton X-100. The fixed
cells were incubated with specific antibodies at the appropriate dilutions
(see above) for 30 min at room temperature. To stain actin, the fixed cells
were incubated with TRITC-conjugated phalloidin (Sigma-Aldrich; dilu-
tion 1:500 in PBS). After staining, coverslips were mounted in GEL/
MOUNT™ (Biomeda Corp.) or Elvanol.
Fluorescent images were recorded with an Axiophot microscope (Carl
Zeiss, Inc.) equipped for fluorescence using 
 
3
 
66/1.4 or 
 
3
 
100/1.3 objectives.
 
Immunoblotting
 
For detecting adhesion molecule levels and phospho-enzyme status, cells
were lysed in sample buffer containing 50 mM TRIS-HCl, pH6.8, 5%
2-mercaptoethanol, 3% sodium dodecyl sulfate, 0.5 mg/ml bromophenol-
blue and phosphatase inhibitors, followed by a 10-min incubation at 100
 
8
 
C.
Detergent-soluble and -insoluble fractions were obtained by lysing the at-
tached cells on the plate in Triton X-100 buffer (50 mM Mes, pH 6.0, 0.5%
Triton X-100, 2.5 mM EGTA, 5 mM magnesium acetate, 0.4 mM AEBSF,
10 
 
m
 
g/ml aprotonin, 10 
 
m
 
g/ml leupeptin, 1 mM Na
 
3
 
VO
 
4
 
, 20 mM NaF, 5
mM sodium pyrophosphate) with gentle agitation for 2 min at room tem-
perature. The lysates were collected, centrifuged for 2 min at 20,000 
 
g
 
, and
the supernatants were saved (Triton-soluble fractions). The remaining ma-
terial on the plate was washed and dissolved in sample buffer to give the
Triton X-100–insoluble fraction. Aliquots of cell extracts containing equal
amounts of protein were resolved by 10% SDS-PAGE and electroblotted
onto nitrocellulose filters. The membranes were blocked with TBS-tween
containing 5% low-fat milk (blocking solution), incubated with primary
antibodies overnight at 4
 
8
 
C, and then with HRP-conjugated secondary an-
tibodies for 75 min at room temperature. Immunoreactive bands were vi-
sualized using enhanced chemiluminescence.
 
Results
 
HR12 Blocks the Effects of ras Transformation on 
Cell–Matrix Adhesion, Cell–Cell Contacts, and Actin 
Reorganization in Rat1 Cells
 
We examined the effect of the Ras-FTI, HR12, on Rat1/
ras cells (fibroblasts stably transformed with Ha-
 
ras
 
V12
 
). 
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Figs. 1–3 show a comparison of nontransformed Rat1 cells,
Rat1/ras cells, and HR12-treated Rat1/ras cells (48 h, 20
 
m
 
M). Transformation of Rat1 cells with activated Ha-
 
ras
 
resulted in the disruption of 
 
b
 
-catenin and vinculin-con-
taining cell–cell contacts (Figs. 1 and 3). Stress fibers, la-
beled by TRITC-phalloidin, were also disrupted (Fig.
2). Cell–matrix adhesions, observed by labeling paxillin,
phospho-tyrosine, and vinculin, were lost (Fig. 3).
The effects of HR12 were seen within 24 h of treatment
(Fig. 1 b), as manifested by considerable cell spreading and
the acquisition of a more epithelial morphology. These ef-
fects were evident with as little as 1 
 
m
 
M HR12 (data not
shown). At 24 h, 
 
b
 
-catenin distribution was still largely dif-
fuse, with occasional dot-like cell–cell adhesions (Fig. 1 b),
but, by 48 h, most of the 
 
b
 
-catenin was associated with ex-
tensive arrays of adherens junctions (Fig. 1 c) and the dif-
fuse cytoplasmic labeling was markedly reduced. By 72 h,
the junctions were labeled even more extensively (Fig. 1
d), and were essentially indistinguishable from those of
control Rat1 cells (Fig. 1 f). Upon removal of HR12 for
24 h (after a 48-h incubation with the drug), cell–cell adhe-
sion markedly deteriorated, leaving only a few sporadic
junctions (Fig. 1 e).
In Rat1 cells, F-actin was engaged as a dense web of
conspicuous stress-fibers (Fig. 2 f). These actin bundles
were assembled into either parallel arrays terminating in
cell-substrate focal contacts or circumferential arrays
running along the intercellular junctions. This filament
network was disrupted in Rat1/ras cells. Rat1/ras cells
 
appeared elongated, with numerous F-actin–containing
protrusions and ruffles, but essentially no actin bundles
(Fig. 2 a). Within 24 h in the presence of HR12, the cells
flattened, developing parallel arrays of large bundles. At
48 h and later, circumferential bundles also became appar-
ent (Fig. 2, c and d). Removal of HR12 for 24 h, after a 48-h
treatment, resulted in the loss of organized actin bundles
and the appearance of a more diffuse pattern (Fig. 2 e).
Immunofluorescence labeling with anti-paxillin, anti-
phosphotyrosine, and anti-vinculin showed that Rat1 cells
contained prominent focal adhesions (Fig. 3). Rat1/ras
cells had far fewer and smaller focal adhesions and diffuse
staining patterns. The addition of HR12 to Rat1/ras cells
for 48 h or longer resulted in complete restoration of focal
adhesions, as defined by labeling with the three antibod-
ies. In fact, often the labeling patterns obtained in HR12-
treated cells were more extensive than those found in un-
treated Rat1 controls.
In parallel to monitoring the localization and assembly
of the adhesion molecules, we measured their levels in the
cells using quantitative immunoblotting. Rat1/ras cells
were treated with HR12 at various concentrations for 48 h,
and then lysed in sample buffer. Cell lysates were then sub-
jected to immunoblotting with antibodies to 
 
b
 
-catenin,
pan-cadherin, and phosphotyrosine. Fig. 4 shows an HR12
dose-dependent increase in 
 
b
 
-catenin and cadherin levels.
The antibody against phosphotyrosine (PY20) recognizes
two major bands (125 and 135 kD), whose intensities in-
crease 5- and 10-fold respectively. The lower band corre-
Figure 1. HR12 treatment in-
duces adherens junction organi-
zation in ras-transformed Rat1
cells. Rat1/ras cells grown in me-
dium containing 10% FCS were
exposed to 20 mM HR12, fixed,
and stained with anti–b-catenin
antibody and Cy3-conjugated
anti–mouse antibody. (a) No
treatment; (b–d) time course of
exposure to HR12: (b) 24 h, (c)
48 h, and (d) 72 h. (e) Cells were
exposed to HR12 for 48 h,
washed, and incubated in me-
dium containing 10% FCS 24-h
longer, before fixation. (f) Un-
transformed Rat1 cells are shown
for comparison. Bar, 10 mm. 
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lates well with the band recognized by anti–focal-adhesion-
kinase antibody (data not shown). This is in agreement
with the immunofluorescence data, which showed intense
staining of focal adhesions in Rat1/ras cells treated with
HR12, using antiphosphotyrosine antibody (Fig. 3).
Actin exists in a dynamic equilibrium between a Triton-
soluble pool and Triton-insoluble cytoskeletal filaments.
Fig. 2 shows that HR12 triggers dramatic assembly of actin
into stress fiber networks in Rat1/ras cells. In parallel, we
show the translocation of actin from the Triton-soluble
into the Triton-insoluble fraction of Rat1/ras cells treated
with increasing concentrations of HR12 (Fig. 4, bottom).
 
HR12 Treatment of Rat1/ras Cells Inhibits Ras 
Processing and Erk Phosphorylation
 
We next examined the effects of HR12 on the pathways
downstream to Ras, which might be responsible for the
morphological changes induced by HR12. These cascades
include MAPK pathways and the PI-3
 
9
 
kinase pathway.
Rat1/ras cells treated with HR12 for 48 h were lysed and
immunoblotted with anti-Ras antibody. Unprocessed Ras
migrates more slowly than its processed form in SDS-
PAGE. Fig. 5 shows the shift of Ras towards its unpro-
cessed form with increasing concentrations of HR12, with
an IC
 
50
 
 of 1 
 
m
 
M. The same blots were reacted with anti-
bodies recognizing the activated forms of MAPKs (anti–
double-phosphorylated Erk, Jnk, or p38), or the activated
form of PKB (antiphospho-Thr308-Akt). The total level of
each enzyme was determined using antibodies that recog-
nize both phosphorylated and nonphosphorylated forms
of the enzyme. Enzyme activation was quantified by deter-
 
mining the ratio between the level of the phosphorylated
enzyme and its total level. HR12 induced a dose-depen-
dent decrease in Erk and Jnk activation and a dose-depen-
dent increase in p38 and PKB activation (Fig. 5).
The inhibition of Erk1&2 phosphorylation induced by
HR12 exhibited an IC
 
50
 
 value of 1 
 
m
 
M (Fig. 5), comparable
with the IC
 
50
 
 for the inhibition of Ras processing (Fig. 5).
The high apparent level of phosphorylation of Erk2 in un-
treated Rat1/ras cells was probably due to the very low ex-
pression of Erk2 in these cells. We noticed that the Erk2
level was inversely correlated with its activation state
(Figs. 5 and 6). Comparison of the phosphorylation state of
Erk1&2 in nontransformed Rat1 cells to that in Rat1/ras
cells, showed that transformation with active Ras dramati-
cally induced Erk1&2 phosphorylation (5- and 35-fold, re-
spectively), while treatment with HR12 brought Erk-phos-
phorylation back to the level that exists in Rat1 cells.
The kinetics of the decline in Erk phosphorylation in re-
sponse to HR12 treatment corresponded to the kinetics of
the increase in the levels of nonfarnesylated Ras (Fig. 6).
For the first 15 h of HR12 treatment, there was a gradual
decrease in Erk activation, which closely correlated with
the inhibition of Ras farnesylation by HR12. At 15 h of
HR12 treatment, most of the Ras population was unpro-
cessed and the inhibitory effect on Erk phosphorylation
was maximal. Unprocessed Ras continued to accumulate
after 15 h of treatment with HR12. However, the phos-
phorylation level of Erk was already at its lowest value after
15 h of exposure. The amount of active cytosolic Ras accu-
mulated at 15 h would appear to be sufficient to titrate the
Raf molecules in the cell, thus achieving the maximal in-
Figure 2. HR12-treatment induces
stress-fiber formation in Rat1/ras cells.
Rat1/ras cells were treated as in Fig. 1
and stained with TRITC-labeled phal-
loidin. (a) No treatment, (b) 24 h, (c)
48 h, (d) 72 h, and (e) 48 h exposure to
HR12, followed by 24 h without the in-
hibitor. (f) Untransformed Rat1 cells.
Bar, 10 mm. 
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hibitory effect on Mek activation (Lerner et al., 1995). In
summary, the Raf/Mek/Erk pathway seems to be dramati-
cally affected by HR12.
 
Mek Inhibition by PD98059 Causes Rat1/ras 
Morphological Reversion, Induction of Cell–Cell and 
Cell–Matrix Adhesion and Stress Fiber Formation
 
To test whether the Mek/Erk pathway mediates the Ras ef-
fect on the cytoskeleton and cell adhesion, we specifically
inhibited the Mek/Erk cascade. Fig. 7 shows that a 24-h in-
cubation with the Mek inhibitor, PD98059, induced pheno-
typic reversion almost indistinguishable from that induced
by HR12. The cells became spread and flattened. 
 
b
 
-cate-
nin–containing adherens junctions were assembled, stress
fibers were formed, and vinculin-labeled cell–matrix con-
tacts were reestablished. The morphology of Rat1/ras cells
treated with either HR12 or PD98059 was indistinguishable
from that of parental Rat1 cells. These findings suggest that
the Ras-Mek-Erk pathway plays a pivotal role in the regu-
lation of the cytoskeleton and the cell adhesions.
 
Activated Mek1 Disrupts Adherens Junctions and 
Stress Fiber Formation
 
To further characterize the role of the Ras/Mek/Erk path-
way in the regulation of adherens junctions, cell–matrix
contacts, and stress fibers, we examined the morphological
consequences of the expression of an activated form of
Mek1 in Rat1/ras treated with HR12 or in untreated Rat1
cells. Rat1/ras and Rat1 cells were transiently cotrans-
 
fected with plasmids encoding GFP and constitutively ac-
tive MEK [MAPKK1(
 
D
 
N3)] (Mansour et al., 1994). 24 h
later, Rat1/ras cells were treated with 20 
 
m
 
M HR12 for
48 h. Cells were then fixed and stained with anti–
 
b
 
-catenin
or phalloidin (Fig. 8). Examination of the transfected cells
(identified by GFP expression) revealed a loss or reduction
in 
 
b
 
-catenin–containing adherens junctions. This effect was
most prominent when the neighboring cells were trans-
fected as well (Fig. 8). Labeling of actin indicated that
MAPKK1(
 
D
 
N3)-transfected cells lost stress fibers (com-
pared with nontransfected neighboring cells). These effects
were not observed when the empty vector was transfected
into the cells. Thus, overexpressing activated Mek itself is
sufficient to disrupt cell–cell contacts and stress fibers.
 
The Effect of HR12 on PI-3
 
9
 
kinase and PKB
 
We used the selective inhibitor of PI-3
 
9
 
kinase, LY294002,
to examine the role, if any, of PI-3
 
9
 
kinase in transducing
the Ras effect on cell adhesion and stress-fiber formation.
Rat1/ras cells were exposed to 10 
 
m
 
M LY294002 for 48 h
in DME containing 10% FCS, fixed, and stained with anti–
 
b
 
-catenin, anti-vinculin, and TRITC-phalloidin, as de-
scribed in Materials and Methods. LY294002 treatment
was found to have no effect on cell–cell contact, cell–
matrix adhesion, or stress-fiber formation in Rat1/ras cells
(Fig. 7). Surprisingly, PKB, a well-established downstream
target of PI-3
 
9
 
kinase (Alessi and Cohen, 1998; Kandel and
Hay, 1999), was activated after HR12 treatment of Rat1/
ras cells, rather than inhibited (Fig. 5). The elevation in
Figure 3. HR12 leads to morphological reversion of ras-transformed cells and increases dramatically cell–matrix adhesion and cell–cell
contacts. Rat1 and Rat1/ras cells are compared with Rat1/ras cells that were exposed to 20 mM HR12 for 48 h. The fixed cells were
stained with anti–paxillin, anti–vinculin, or antiphosphotyrosine mAb, followed by Cy3-conjugated anti–mouse antibody. Bar, 10 mm. 
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Figure 4. HR12 treatment of Rat1/ras cells causes elevation of
adhesion molecule levels in a dose-dependent manner. Whole-
cell lysates were immunoblotted with anti–b-catenin or anti–
pan-cadherin or antiphosphotyrosine (pY20) mAb. Actin lev-
els in the Triton X-100 insoluble and soluble fractions were
detected by polyclonal anti–actin antibody. The levels of
b-catenin, cadherin, phosphotyrosine, and actin were quanti-
fied using the NIH-IMAGE 1.61 program.
 
PKB phosphorylation might be induced by the cadherin-
or integrin-mediated signaling pathways as a secondary ef-
fect of HR12 (see Discussion). Our findings suggest that
PKB phosphorylation might be induced by the cadherin-
or integrin-mediated signaling pathways as a secondary ef-
fect of HR12 (see Discussion). Our findings suggest that
PI-3
 
9
 
kinase does not play a role in the organization of ad-
herens junctions, cell–matrix contacts, or stress fibers in-
duced by HR12 in Rat1/ras cells.
 
Differential Effect of HR12 on Jnk and p38
 
We also examined the possible role of the two other
MAPK pathways in mediationg Ras signaling to the cy-
toskeleton. Fig. 5 shows that Jnk phosphorylation is inhib-
ited by HR12 in a dose-dependent manner. Jnk phosphor-
ylation in Rat1 cells is lower (2.5-fold) than in Rat1/ras
cells. The difference between Erk phosphorylation in Rat1
versus Rat1/ras cells was much more striking (see above).
The relevance of Jnk inhibition to the morphological
effects of HR12 was examined using a plasmid-express-
ing dominant-negative SEK (SEK-AL) (Zanke et al.,
1996a,b). Sek is the direct activator of Jnk. To detect trans-
fected cells, we cotransfected the SEK-AL plasmid with a
plasmid expressing GFP. Adherens junctions were labeled
using anti–
 
b
 
-catenin antibodies, and stress fibers were vi-
sualized by TRITC-phalloidin. No effect of the dominant-
interfering SEK on adherens junctions and stress-fiber for-
mation was detected (data not shown).
In many biological systems, and in particular in fibro-
blasts grown in culture, p38 and Jnk are often coactivated.
Yet we saw a differential effect of HR12 on these two
pathways. As seen in Fig. 5, p38 phosphorylation levels in-
creased up to 10-fold in Rat1/ras cells treated with HR12,
whereas Jnk phosphorylation levels dropped, as discussed
above. Phosphorylation of p38 in Rat1 cells was fivefold
stronger than in Rat1/ras cells. The HR12-induced in-
crease in p38 phosphorylation in Rat1/ras cells was dose
dependent: at 4.5 
 
m
 
M HR12, the p38 phosphorylation
level was similar to that in nontransformed Rat1 cells. To
examine the possible relevance of p38 activation to the
changes in the morphological features induced by HR12,
we tested whether SB203580, an inhibitor of p38 activity,
antagonizes the effect of HR12 on actin reorganization.
When Rat1/ras cells were treated with 20 
 
m
 
M HR12 and
10 
 
m
 
M SB203580, or Rat1 cells with 10 
 
mM SB203580,
some interference with stress fiber formation was noted
(data not shown). Since the specificity of the inhibitor
SB203580 is controversial, the question of the relevance of
p38 remains unresolved (see Discussion).
Phenotypic Reversion Induced by HR12 Results from 
Ras Inhibition Rather than Inhibition of Other 
Farnesylated Proteins
To test whether the cytoskeletal effects of HR12 described
here were due to the inhibition of Ras farnesylation,
rather than inhibition of some other protein(s), we investi-
gated the effect of HR12 on cells transformed with myri-
stoylated oncogenic-ras (myr-ras). The anchorage of myri-
stoylated-Ras to the membrane does not depend on
farnesyltransferase activity. The morphology of fibroblasts
transformed by myr-ras is therefore expected to not be af-
fected by HR12, if the phenomena described result exclu-Reuveni et al. Mek-mediated Reversal of Ras Transformation by FTI 1185
sively from the inhibition of Ras farnesylation. If, how-
ever, other farnesylated proteins downstream of Ras; e.g.,
RhoB (Lebowitz and Prendergast, 1998), are responsible
for the phenotype, one would expect HR12 to be in-
hibitory. We treated v-Ha-ras– and myr-ras–transformed
NIH3T3 fibroblasts with 20 mM HR12 for 48 h. Cells were
stained with anti-vinculin antibody. HR12 treatment re-
stored focal contacts in NIH3T3v-ras, but had no effect on
vinculin distribution in NIH3T3myr-ras (Fig. 9 a).
Since our findings point to the Mek/Erk pathway as a
transducer of the Ras effect on the cell morphology and
cated concentrations of HR12 for 48 h, lysed, and immunoblotted
with anti–Ras to allow dose–dependent inhibition of Ras process-
ing. (up) Unprocessed Ras, (p) processed Ras. In parallel, blots
were labeled with antiphosphorylated Erk (pErk), anti–Erk2
(Erk), antiphosphorylated-p38 (pp38), anti–p38 (p38), antiphos-
pho-Jnk (pJnk), anti–Jnk (Jnk), antiphospho-PKB/Akt (pPKB),
and anti–PKB/Akt (PKB). In each case, the level of phosphoen-
zyme was normalized to the level of total enzyme. For compari-
son, phosphoenzyme levels in Rat1 cells are shown (right lane).
Figure 6. Correlation between the inhibition of Ras processing
and inactivation of Erk. Rat1/ras cells grown in DME containing
10% FCS were treated with 20 mM HR12 for the indicated time
periods, or exposed to 20 mM HR12 for 48 h, washed, and incu-
bated without the inhibitor 24 h longer, before lysis (wash). Ly-
sates were immunoblotted with anti–Ras, antiphosphorylated
Erk (pErk), and anti–Erk2 (Erk) antibodies.
Figure 5. HR12 treatment of Rat1/ras cells inhibits Ras process-
ing and affects the phosphorylation levels of MAPKs and PKB in
a dose-dependent manner. Rat1/ras cells were exposed to the indi-The Journal of Cell Biology, Volume 151, 2000 1186
adhesion, we also examined ERK phosphorylation lev-
els in these cells. Cell lysates from both cell types, with
and without HR12 treatment, were immunoblotted with
antiphospho-Erk antibody. Blots were then stripped
and reacted with anti-Erk2 antibody. HR12 inhibited
Erk phosphorylation in NIH3T3v-ras, but did not in-
hibit Erk phosphorylation in NIH3T3myr-ras (Fig. 9
b). Both cell lines exhibited enhanced Erk phosphor-
ylation, compared with the parental nontransformed
NIH3T3.
Discussion
Among the most striking manifestations of the trans-
formed phenotype are the severe disruption of the actin
cytoskeleton and the loss of cell–matrix and cell–cell adhe-
sions (Behrens et al., 1992; Hunter, 1997). These cellular
changes contribute directly to the anaplastic appearance
of tumors in vivo and to their deregulated growth, invasive
properties, and metastatic potential (Birchmeier et al.,
1993; Christofori and Semb, 1999). It is therefore impor-
Figure 7. Inhibition of Mek/Erk
pathway by PD98059 causes
morphological reversion of ras-
transformed Rat1 cells. Rat1/ras
grown in DME containing 10%
FCS were treated for 24 h with
50  mM PD98059 or 0.05%
DMSO (veh), and fixed. b-Cate-
nin, actin, or vinculin were la-
beled as described in Materials
and Methods. Bar, 10 mm.Reuveni et al. Mek-mediated Reversal of Ras Transformation by FTI 1187
tant to determine the molecular mechanisms responsible
for these cellular changes.
Oncogenic ras, which is one of the most powerful onco-
genes, is frequently associated with human cancer and has
been shown to dramatically affect the cytoskeleton. Acti-
vated Ras affects actin organization (Lombardi et al., 1990;
Moustakas and Stournaras, 1999), assembly of focal adhe-
sions, and the formation of adherens junctions (Izawa et al.,
1998; Hegland et al., 1999) and tight junctions (Yamamoto
et al., 1997; Chen et al., 2000a). Farnesyltransferase inhibi-
tors have been shown to induce morphological reversion of
ras-transformed fibroblasts (Rat1/ras), and to restore stress-
fiber formation (Prendergast et al., 1994). Here we show,
for the first time, that application of a novel FTI, HR12
(Reuveni et al., 1997), to Rat1/ras cells induces complete re-
covery of cell–cell adherens junctions, with a concomitant
rise in the levels of the junctional protein components, cad-
herin and b-catenin. Furthermore, HR12 induces assembly
of vinculin, paxillin, and phosphotyrosine-containing focal
contacts, and restores normal stress fibers. HR12 also inhib-
its potently the invasive growth of Rat1/ras cells (data not
shown). Loss of functional cell–cell junction complexes is a
critical step in the progression of cancer from noninvasive
to invasive (Birchmeier et al., 1995; Christofori and Semb,
1999), and is detected in the progress of most human can-
cers (Behrens, 1999). Moreover, it has been shown that
E-cadherin plays a role in the suppression of tumor invasion
in cultured cells and in mouse models (Christofori and Semb,
1999). E-cadherin also functions in the suppression of cell
growth (St. Croix et al., 1998; Levenberg et al., 1999), con-
sistent with our unpublished observations that HR12 inhib-
its growth of Rat1/ras cells, with minimal effects on non-
transformed Rat1 cells. We propose that the elevation in
cadherin levels and recovery of adherens junctions induced
by HR12 may be the mechanism whereby FTI suppresses
invasion and induces growth arrest.
Being a pivotal regulator of many signaling pathways,
Ras could, in principle, exert its cytoskeletal and junc-
tional effects via several distinct pathways. In this study,
we have examined the effect of HR12 on the main path-
Figure 8. Activated Mek dis-
rupts adherens junctions and
stress fibers. Rat1/ras (center)
and Rat1 (right) cells were tran-
siently cotransfected with vec-
tors carrying GFP and activated-
MEK [MAPKK1(DN3)]. 24 h
after transfection, the Rat1/ras
cells were treated with 20 mM
HR12 for 48 h. Cells were fixed
and stained with anti–b-catenin
or phalloidin. In cells that
showed GFP fluorescence, indi-
cating that they had been trans-
fected, stress fibers and adher-
ens junctions were disrupted.
Arrowheads indicate b-catenin–
labeled adherens junctions in
the nontransfected cells, while
arrows indicate their loss in
the MAPKK1(DN3)-transfected
cells. In Rat1/ras cells trans-
fected with the GFP-vector
alone and treated with HR12
(left), the stress fibers and adhe-
rens junctions remained intact.
Bar, 10 mm.The Journal of Cell Biology, Volume 151, 2000 1188
ways downstream of Ras, namely the MAP-kinase cas-
cades and the PI-39kinase pathway. To assign which of
these pathways mediates the effects of Ras on the cyto-
skeleton and cell adhesions, we examined the effects of se-
lective inhibitors.
The Role of the Ras to Erk Pathway
Our results point to the Mek/Erk pathway as the main
route mediating the recovery of adherens junctions, focal
adhesion loci, and stress fibers induced by Ras inhibition
in Rat1/ras cells. Several lines of evidence support this no-
tion. First, using Ha-ras–transformed Rat1 fibroblasts, we
show that inhibition of Ras farnesylation by the farnesyl-
transferase inhibitor HR12 results in a dose-dependent de-
crease in Erk activation, which parallels the dose-depen-
dent inhibition of Ras farnesylation (Fig. 5) and the
morphological changes (data not shown). Second, the ki-
netics of soluble Ras accumulation induced by HR12
treatment and the kinetics of Mek/Erk inactivation are
identical (Fig. 6) and precede the observed morphological
changes. The Mek inhibition can most probably be ac-
counted for by the titration of Raf by the soluble, unpro-
cessed oncogenic-Ras protein (Lerner et al., 1995). Third,
the HR12-induced morphological reversion of Rat1/ras
cells to the untransformed phenotype characteristic of the
parental Rat1 cells is fully mimicked by the selective Mek
inhibitor PD98059 (Fig. 7). We show identical effects of
HR12 and PD98059 treatments on the reformation of cell–
cell contacts, cell–matrix adhesions, and actin reorganiza-
tion (Fig. 7). Finally, the finding that a constitutively acti-
vated form of Mek, MAPKK1(DN3), induces disruption of
adherens junctions and reduction of stress-fiber content in
nontransformed Rat1 cells as well as in Rat1/ras cells
treated with HR12 (Fig. 8), strongly supports the notion
that the Ras to Erk pathway is a major pathway through
which morphological transformation occurs in these cells.
Further support comes from a recent report showing that
inhibition of Erk activity in PC12 cells and in ras-trans-
formed MDCK cells resulted in increased synthesis of cad-
herin and b-catenin (Lu et al., 1998; Chen et al., 2000a).
Taken together, these findings suggest that the level of ad-
herens junction proteins is regulated by the Ras to Erk
pathway in a variety of cell types. The Ras to Erk pathway
also seems to be involved in stress-fiber formation. Al-
though it was reported that stress-fiber formation is regu-
lated by Rho (Ridley and Hall, 1992; Zohn et al., 1998), we
and others (Reszka et al., 1997; Plattner et al., 1999) find
the Mek/Erk pathway to be the major regulator of these
structures. Moreover, the Mek/Erk pathway is reported to
have an essential role in metastasis and morphogenesis in
epithelial cells (Montesano et al., 1999; Sebolt-Leopold et
al., 1999). In particular, of the known Ras effectors, only
Raf was able to induce metastasis (Webb et al., 1998). The
molecular mechanism by which Raf mediates tumor inva-
sion and metastasis may involve the key role of the Raf/
Mek/Erk pathway in the regulation of cell adhesion and
stress-fiber formation.
The mechanism by which Mek or Erk delivers the signal
to the cytoskeletal components is still unknown. We detect
initial actin cytoskeleton reorganization z6 h after Mek is
inhibited, and full recovery is attained within 15 h of treat-
Figure 9. Phenotypic reversion by HR12 depends on inhibition
of Ras function. (a) HR12 treatment increases cell adhesion of
v-ras–transformed NIH3T3 cells, but not of myristoylated-ras–
transformed cells. After a 48-h treatment with 20 mM HR12 in
DME 1 10% FCS, the cells were fixed and stained with anti–vin-
culin mAb followed by Cy3-conjugated anti–mouse antibody.
Bar, 10 mm. (b) Erk phosphorylation is inhibited by HR12 in
NIH3T3v-ras, but not in NIH3T3myr-ras. Cell lysates were im-
munoblotted with antiphosphorylated-Erk mAb (pErk). The
blot was stripped and reacted with polyclonal anti–Erk2 anti-
body. Phospho-Erk levels were normalized to total Erk levels.Reuveni et al. Mek-mediated Reversal of Ras Transformation by FTI 1189
ment with PD98059. The establishment of adherens junc-
tions, however, has a delayed time course. It is first de-
tected after 10 h of treatment and complete structures
develop 19 h after Mek is inhibited (data not shown).
These relatively slow time courses suggest that the induc-
tion of these structures is not delivered by a direct signal,
but rather involves a novel gene expression induced by the
inhibition of the Ras to Erk pathway. The increases in the
levels of the junction components, b-catenin and cadherin,
subsequent to HR12 treatment (Fig. 4) support this no-
tion. One of the known substrates of Erk, which might
serve as a potential mediator of Erk signaling to the cy-
toskeleton, is the transcription factor Ets-1/2 (McCarthy et
al., 1997). Recent reports have shown that expression of
dominant-negative Ets leads to increased spreading of the
cell, cytoskeletal organization, and enhanced cell–matrix
adhesion (Mattot et al., 2000), as does Erk inhibition in
our case. Whether Erk signals directly by phosphorylating
cytoskeletal and junctional components, or indirectly by
controlling their protein levels through transcription,
translation, or degradation remains to be seen.
The Role of Jnk and p38
Jnk activation in Rat1/ras cells is much lower than Erk1&2
activation, but is inhibited in a dose-dependent manner by
HR12 (Fig. 5). Since the overexpression of SEK-AL, a
dominant negative Jnk activator, has no attenuating effect
(data not shown), we believe that the involvement of Jnk
is minimal or nonexistent. Although Jnk and p38 are often
coactivated, we find that treatment of Rat1/ras cells by
HR12 results in a dose-dependent increase in the activity
of p38 (Fig. 5). Application of the selective p38 kinase in-
hibitor SB203580 partially antagonizes the effect of HR12
(data not shown). Since SB203580 was reported recently
to activate Raf-1 (Hall-Jackson et al., 1999; Kalmes et al.,
1999), and since we show that blocking Mek activity in
Rat1/ras cells is sufficient to induce stress fiber formation
(Fig. 7), the effect of SB203580 may also be accounted for
by reactivation of the Mek/Erk pathway downstream of
Raf-1. However, Hall-Jackson et al. (1999) and Kalmes
et al. (1999) saw no stimulation of Mek or Erk, although
Raf-1 was activated in cells treated with 10 or 25 mM
SB203580. Another side effect of SB203580, reported re-
cently, is inhibition of PKB phosphorylation (Lali et al.,
2000), which we found also in Rat1/ras cells (data not
shown). We find, however, that PKB activation has no role
in the HR12 effect on the cytoskeleton (Fig. 7), so this in-
hibition seems irrelevant. A few reports suggest that p38
activation is indeed required for actin reorganization,
probably through activation of MAPKAP-kinase-2, a p38
substrate. MAPKAP-kinase-2 in turn phosphorylates HSP27,
a modulator of actin polymerization (Huot et al., 1998;
Matsumoto et al., 1999; Ono and Han, 2000). In particular,
stress-fiber formation was reported to be a consequence of
enhanced actin polymerization induced by p38 activation
and of assembly of focal adhesions induced by FAK phos-
phorylation (Rousseau et al., 2000).
We find that p38 is also activated by treatment of Rat1/
ras cells with the Mek inhibitor PD98059 (data not shown),
suggesting that the activation of p38 lies downstream to
Mek inhibition, as suggested also by others (Berra et al.,
1998). To further discriminate between the effects of
SB203580 on Raf activation and p38 inhibition, and to ex-
plore the potential role for p38 in the pathway leading to
stress-fiber induction, we examined whether SB203580 an-
tagonizes the effects of PD98059. An antagonistic effect
would rule out Raf activation as the mediator of the
SB203580 effect, since Mek is not active in the presence of
PD98059. We observed that in the presence of SB203580
the content of stress fibers induced by PD98059 or HR12 is
reduced (data not shown), thus the activation of p38, in-
duced by the inhibition of the Ras-Erk pathway, probably
does play a role in the morphological reversion induced by
HR12. This interesting nuance deserves further attention.
No Role for PI-39Kinase
PI-39kinase was reported to be a Ras effector (Rodriguez-
Viciana et al., 1994, 1996), mediating signals from Ras to
the actin cytoskeleton (Rodriguez-Viciana et al., 1997)
and to adherens junctions (Potempa and Ridley, 1998) in a
variety of cell lines. If the Ras effects studied here are also
transmitted via PI-39kinase, we would expect the PI-
39kinase inhibitor LY294002 to mimic the effects of HR12.
Our finding that LY294002 has no effect on stress fibers
and junctions in Rat1/ras cells (Fig. 7), implies that the pu-
tative PI-39kinase inhibition, due to inhibition of Ras far-
nesylation, cannot account for the effects of HR12 on the
cytoskeleton and adhesion.
In fact, application of HR12 to Rat1/ras cells for 48 h
results in dose-dependent activation of PKB (Fig. 5), a
well-established downstream target of PI-39kinase (Alessi
and Cohen, 1998; Kandel and Hay, 1999). We examined
whether PKB activation is responsible for the observed
cytoskeletal recovery. In this case, we would expect inhi-
bition of PI-39kinase/PKB pathway by LY294002 to op-
pose the effects of HR12. We treated Rat1/ras cells with
a combination of HR12 and LY294002, but the effects
of HR12 on stress-fiber formation, adherens junction,
and focal adhesion assembly were not counteracted by
LY294002 (data not shown). Moreover, we observed no
activation of PKB during short exposures to HR12 (up to
20 h, data not shown), implying that the phosphorylation
of PKB is not a direct consequence of HR12 treatment.
We further wondered whether glycogen synthase kinase 3
(GSK3), whose activity is known to be repressed by PKB
(Cross et al., 1995; van Weeren et al., 1998), could medi-
ate the HR12-induced increase in b-catenin levels, as acti-
vation of GSK3 is known to lead to b-catenin degradation
(Ben-Ze’ev and Geiger, 1998). But treatment of Rat1/ras
cells with HR12 did not cause increased phosphorylation
of GSK3 (data not shown), and GSK3 phosphorylation
levels were similar in Rat1/ras and Rat1 cells (data not
shown). Thus it seems that signaling pathways emanating
from Ras to PI-39kinase, including PKB, are not involved
in the HR12-induced morphological reversion. We be-
lieve that the increase in PKB phosphorylation is a sec-
ondary effect of the cytoskeletal recovery induced by
HR12. The induction of PKB phosphorylation parallels
that of cytoskeletal recovery, supporting this contention.
Integrin-linked kinase (ILK) and cadherin are both
known to be involved in activation of PKB (Delcom-
menne et al., 1998; Pece et al., 1999). ILK activity may beThe Journal of Cell Biology, Volume 151, 2000 1190
reinstated once the integrin fabric is restored due to
HR12 treatment, and we have shown (Fig. 1) that cad-
herin was activated upon HR12 treatment. Thus, both
ILK and cadherin are likely to be responsible for the PKB
phosphorylation detected in our study. The observed
HR12-induced increase in b-catenin levels is probably
mediated by PI-39kinase–independent activation of cad-
herin (Sadot et al., 1998).
Is the HR12 Effect Mediated Solely by Ras Inhibition?
In this report, we used the FTI, HR12, as a tool for Ras in-
hibition. A series of studies using other FTIs, L-739,749
(Prendergast et al., 1994; Lebowitz et al., 1995) and
L-744,832 (Du et al., 1999), suggests that the cytoskeletal
events induced by FTI are not mediated by the inhibition
of Ras farnesylation. Rather, these studies suggest that the
reduction in the proportion of the farnesylated-RhoB, and
the consequent increase in the proportion of geranylgera-
nylated-RhoB, lead to the morphological effects of their
FTIs in Rat1/ras cells (Lebowitz and Prendergast, 1998;
Du et al., 1999; Prendergast, 2000). The main arguments in
favor of the RhoB theory are: (a) the half life of farnesy-
lated Ras is 24 h, which is too long to mediate the morpho-
logical reversion induced by their FTI (18–24 h; Prender-
gast et al., 1994); (b) NIH3T3myr-ras cells, which are not
dependent on farnesylation for Ras function, were sensi-
tive to their FTI in an assay for anchorage-independent
growth (Lebowitz et al., 1995); and (c) there is insufficient
accumulation of soluble oncogenic Ras to interfere with
the functioning of the prenylated Ras (Prendergast et al.,
1994). Our data do not support this hypothesis, but rather
suggest that inhibition of Ras farnesylation is the main
mechanism for the morphological reversion and adhesion
changes induced by HR12 in Rat1/ras cells. Moreover, it
has recently been reported that both farnesylated and ger-
anylgeranylated-RhoB inhibit transformation and tumori-
genesis (Chen et al., 2000b). In contrast to the reports
cited above in support of the RhoB theory, we show here:
(a) by 15 h, most of Ras population is unprocessed (Fig. 6),
which corresponds to the kinetics of the morphological
changes (Figs. 1 and 2); (b) NIH3T3myr-ras cells fail to
form adhesions in response to HR12, unlike NIH3T3 cells
transformed by farnesylation-dependent oncogenic ras
(Fig. 9); and (c) HR12 treatment leads to the accumulation
of high levels of oncogenic Ras in the cytoplasm, followed
by potent inhibition of Mek/Erk activation (Figs. 5 and 6).
Lerner et al. (1995) have shown that the accumulation of
inactive Ras–Raf complexes in the cytoplasm leads to the
shut off of the Ras to Mek pathway. Taking together the
above data and the essential role of the Ras regulated Raf/
Mek/Erk pathway for junction and cytoskeleton organiza-
tion, discussed earlier, we conclude that the effect of
HR12 on the construction of stress fibers, adherens junc-
tions, and focal adhesions is mediated primarily by Ras
translocation.
Is the Raf/Mek/Erk Pathway the Sole Pathway 
Mediating the Ras Effect on Adhesion and
the Cytoskeleton?
The findings reported in this study strongly suggest that
the morphological reversion and the recovery of the cy-
toskeletal structure induced by the FT inhibitor HR12 are
mediated by the inhibition of the Ras to Erk pathway. p38
activation, downstream of Mek inhibition, may also be in-
volved. Other studies claim that Rho, a component down-
stream to Ras, mediates the same morphological effects in
Rat1/ras cells, including induction of adherens junctions,
focal adhesions, and stress fibers (Izawa et al., 1998; Du et
al., 1999). Others report that Rac or Cdc42 are regulators
of adherens junctions (Braga et al., 1997; Fischer and
Quinlan, 1998; Kaibuchi et al., 1999). It is difficult to ex-
amine the contribution of Rho family members to the
HR12 effect on the cytoskeleton, because the effects of
Rho activation and inhibition are very rapid (minutes to
hours), while the full effects of HR12 are manifested after
48 h of treatment. It has been suggested that combinations
of several pathways downstream of Ras control cell–cell
adhesion (Potempa and Ridley, 1998) and morphological
transformation (Yang et al., 1998). We do not exclude the
possibility that other Ras-dependent pathways mediate
morphological transformation. Since Ras activates multi-
ple signaling pathways, the relative contributions of each
one to a particular phenotype may differ between cell
types. Our findings, however, do implicate putative Mek
or Erk substrates as mediators of Ras-dependent disrup-
tion of the cytoskeleton in Rat1/ras cells.
Our work shows that HR12 is a powerful tool to inhibit
oncogenic-Ras signaling. HR12 could serve as an anticancer
drug, with particular antimetastatic potential, deriving from
its ability to induce the formation of cell–cell junctions.
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